title: Follow-up in soft tissue sarcomas.
abstract: The strategy for the follow-up of soft tissue sarcomas (STS) after therapy is tailored to the individual risk of recurrence and based on efficient rather than sophisticated methods of observation. Along with advances in the treatment of sarcomas, earlier detection of a less advanced and resectable recurrent disease (local or metastasis-especially to the lungs) can prolong patient survival. Since the majority of STS relapses occur within 5 years after treatment (approximately 80 % of metastases to the lung and close to 70 % of local recurrences within the first 2-3 years), in the period between 2 and 3 years after treatment, it is mandatory to follow-up patients every 3 months and perform careful history and physical examination (especially scars after surgery of the primary site) and a chest X-ray. There is no reason to perform other studies in asymptomatic patients (unless the patient reports symptoms). In case of retroperitoneal or intraperitoneal STS (including gastrointestinal stromal tumor), contrast-enhanced computed tomography of the abdomen and pelvis is recommended as the follow-up modality of choice. In this paper we outline the current recommendations for the follow-up strategy.
authors.affiliation: Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
authors.forename: Piotr
authors.initials: P
authors.lastname: Rutkowski
authors.affiliation: Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
authors.forename: Iwona
authors.initials: I
authors.lastname: Lugowska
keywords: Follow-up; Gastrointestinal stromal tumors; Recurrences; Sarcoma
references.citation: Cancer. 1992 Feb 1;69(3):662-8
references.pmid: 1730117
references.citation: Semin Oncol. 2003 Jun;30(3):413-6
references.pmid: 12870143
references.citation: Cancer. 2011 Nov 1;117(21):4916-24
references.pmid: 21456019
references.citation: Semin Surg Oncol. 1999 Jul-Aug;17(1):83-7
references.pmid: 10402642
references.citation: Clin Orthop Relat Res. 2014 May;472(5):1568-75
references.pmid: 24249538
references.citation: Sarcoma. 2010;2010:506182
references.pmid: 20634933
references.citation: Ann Surg Oncol. 2000 Jan-Feb;7(1):2-3
references.pmid: 10674440
references.citation: Ann Oncol. 2012 Oct;23 Suppl 7:vii92-9
references.pmid: 22997462
references.citation: AJR Am J Roentgenol. 1991 Aug;157(2):353-8
references.pmid: 1853821
references.citation: Ann Oncol. 2009 May;20 Suppl 4:64-7
references.pmid: 19454466
references.citation: Int J Oncol. 2004 Aug;25(2):429-35
references.pmid: 15254741
references.citation: Ann Surg. 1993 Dec;218(6):705-12
references.pmid: 8257219
references.citation: Eur J Radiol. 2009 Oct;72(1):50-3
references.pmid: 19744809
references.citation: Ann Surg Oncol. 2000 Jan-Feb;7(1):9-14
references.pmid: 10674442
references.citation: Clin Radiol. 2000 Mar;55(3):193-7
references.pmid: 10708612
references.citation: JAMA. 2012 Mar 28;307(12):1265-72
references.pmid: 22453568
references.citation: J Ultrasound Med. 2007 Feb;26(2):157-62
references.pmid: 17255176
references.citation: Cancer. 1996 Feb 15;77(4):675-82
references.pmid: 8616759
references.citation: Sarcoma. 2007;2007:34128
references.pmid: 18270541
references.citation: Expert Rev Anticancer Ther. 2010 Feb;10(2):221-32
references.pmid: 20131998
references.citation: J Surg Oncol. 2012 Aug 1;106(2):155-61
references.pmid: 22297812
references.citation: J Surg Res. 2002 Dec;108(2):227-34
references.pmid: 12505046
references.citation: Radiology. 1994 Jan;190(1):263-8
references.pmid: 8259417
references.citation: Eur J Surg Oncol. 2005 Nov;31(9):1020-4
references.pmid: 16171968